دورية أكاديمية
Modeling Clinical Phenotype Variability: Consideration of Genomic Variations, Computational Methods, and Quantitative Proteomics.
| العنوان: | Modeling Clinical Phenotype Variability: Consideration of Genomic Variations, Computational Methods, and Quantitative Proteomics. |
|---|---|
| المؤلفون: | Bai JPF; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA. Electronic address: Jane.Bai@fda.hhs.gov., Yu LR; Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA. |
| المصدر: | Journal of pharmaceutical sciences [J Pharm Sci] 2023 Apr; Vol. 112 (4), pp. 904-908. Date of Electronic Publication: 2022 Oct 21. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6017 (Electronic) Linking ISSN: 00223549 NLM ISO Abbreviation: J Pharm Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2016- : New York, NY : Elsevier Original Publication: Easton, Pa., American Pharmaceutical Assn. |
| مواضيع طبية MeSH: | Proteomics* , Genomics*, Drug Development ; Phenotype ; Biological Variation, Population |
| مستخلص: | Advances in biomedical and computer technologies have presented the modeling community the opportunity for mechanistically modeling and simulating the variability in a disease phenotype or in a drug response. The capability to quantify response variability can inform a drug development program. Quantitative systems pharmacology scientists have published various computational approaches for creating virtual patient populations (VPops) to model and simulate drug response variability. Genomic variations can impact disease characteristics and drug exposure and response. Quantitative proteomics technologies are increasingly used to facilitate drug discovery and development and inform patient care. Incorporating variations in genomics and quantitative proteomics may potentially inform creation of VPops to model and simulate virtual patient trials, and may help account for, in a predictive manner, phenotypic variations observed clinically. Competing Interests: Declaration of Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Published by Elsevier Inc.) |
| فهرسة مساهمة: | Keywords: Computation; Genomic variation; Quantitative proteomics; Quantitative systems pharmacology; Virtual patient population |
| تواريخ الأحداث: | Date Created: 20221024 Date Completed: 20230321 Latest Revision: 20230401 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.xphs.2022.10.016 |
| PMID: | 36279954 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1520-6017 |
|---|---|
| DOI: | 10.1016/j.xphs.2022.10.016 |